Trial Profile

A Randomized, Double-blind, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MET233 in Otherwise Healthy Adult Participants With Obesity or Overweight

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Sep 2025 According to Metsera media release, initial; clinical data from this trial will be featured in a late breaking oral presentation titled- "Pharmacokinetics, weight loss, and tolerability of the ultra-long acting amylin analog MET-233 (LB 14)", at the 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) held September 15-19, 2025, in Vienna, Austria- on Wednesday, September 17; 2:30 - 4:00 P.M. CEST.
28 Jul 2025 According to Metsera media release, 12-week topline monotherapy data expected in late 2025.
09 Jun 2025 Results presented in the Metsera, Inc. Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com